1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mankind Pharma Ltd.

Mankind Pharma Ltd.

2,275.60
INR
-9.90
(-0.43%)
48.19EPS
53.35P/E
1.05TMarket Cap
Oct 26Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
146.42
155.13
194.25
218.41
256.11
302.19
345.92
354.01
Basic EPS, GAAP
25.72
31.59
35.78
32
47.75
49.28
46.35
47.72
Free Cash Flow per Basic Share
21.01
20.59
-35.59
24.49
44.02
46.6
57.76
- -
Dividend per Share
9.09
- -
- -
- -
- -
- -
1
- -
Book Value per Share
87
117.88
153.65
185.61
233.73
347.39
394.85
- -
Tangible Book Value per Share
85.85
116.9
106.36
141.21
191.72
-55.35
4.04
- -
Basic Weighted Avg Shares
401
401
401
401
401
404
413
413
Sales/Revenue/Turnover
58,652
62,144
77,816
87,494
102,593
122,074
142,776
146,111
Operating Margin (%)
25.1
25.9
24.21
18.76
21.83
20.61
19.86
19.59
Depreciation Expense
991
1,190
1,666
3,259
3,983
6,212
8,862
8,901
Net Income, GAAP
10,304
12,654
14,335
12,819
19,129
19,910
19,129
19,695
Effective Tax Rate (%)
26.54
23.56
26.42
21.63
19.06
20.26
16.92
19.62
Profit Margin (%)
17.57
20.36
18.42
14.65
18.65
16.31
13.4
13.48
Working Capital
15,636
25,532
17,834
24,647
44,485
13,247
4,470
- -
LT Debt
532
622
522
283
326
55,402
28,927
- -
Total Equity
36,716
48,629
63,163
76,233
95,758
145,682
165,611
- -
Return on Invested Capital (%)
- -
27.01
22.68
16.99
20.47
12.96
9.72
- -
Return on Capital (%)
- -
28.13
23.67
17.16
21.69
14.04
10.51
- -
Return on Common Equity (%)
- -
30.84
26.36
18.86
22.77
16.8
12.49
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
34,189
- -
LT Borrowings
- -
28,212
- -
LT Finance Leases
- -
714
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
413
413
413
Market Capitalization
906,726
828,051
1,051,333

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
69,542
- -
Cash, Cash Equivalents & STI
- -
21,959
- -
Accounts Receivable, Net
- -
17,295
- -
Inventories
- -
21,445
- -
Total Current Liabilities
- -
65,073
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
34,189
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
28.4%
13.68%
Free Cash Flow
- -
-65.71%
26.63%
Net Income, GAAP
- -
10.42%
-3.92%
Sales/Revenue/Turnover
- -
18.17%
16.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
28,679
30,614
31,988
30,794
122,074
2026
35,704
- -
35,672
34,429
142,776
2027
40,306
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
13.39
16.31
9.45
10.2
49.28
2026
10.62
- -
9.9
13.44
46.35
2027
13.76
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sheetal Arora
Full Time Employees
27,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
262, Okhla Industrial Estate New Delhi DE India 110 020
IPO Date
May 9, 2023
Website
mankindpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India with select international operations. The company offers a diversified portfolio exceeding 500 products across acute and chronic therapeutic areas including anti-infectives (15% domestic sales share), cardiovascular (15%), gastrointestinal (10%), respiratory (9%), anti-diabetic (9%), vitamins/minerals/nutrients (8%), gynaecology (8%), dermatology (5%), pain/analgesics (4%), and neuro/CNS (3%); prominent consumer healthcare brands encompass Manforce condoms, Prega News pregnancy detection kits, Unwanted-72 emergency contraceptives, Gas-O-Fast antacids, HealthOK multivitamins, and AcneStar anti-acne preparations. Founded in 1991 and commencing active operations in 1995, Mankind Pharma maintains headquarters in New Delhi, India, with 30 manufacturing facilities predominantly in Paonta Sahib (Himachal Pradesh), Haridwar (Uttarakhand), and Sikkim; it supports extensive domestic penetration via 16,000+ field force personnel, 13,000+ stockists, and coverage of over 500,000 doctors, deriving 92% of revenues from India across metros/Tier 1 (53%), Tier 2-6/rural (47%), and zones including North (35%), West (23%), South (23%), and East (19%), alongside exports to the US, Mexico, and pharmerging markets. Recent developments include the July 2024 announcement of a INR 13,630 crore acquisition of Bharat Serums and Vaccines (BSV) approved by CCI in October 2024, funded partly by a December 2024 INR 3,000 crore qualified institutional placement; a October 2025 INR 797 crore slump sale acquisition from BSV of its women's health Rx branded generics portfolio to bolster gynaecology offerings; in-licensing of AstraZeneca's Symbicort inhaler and Novartis' Inclisiran for respiratory and cardiac segments respectively during FY24; commissioning of India's first fully integrated dydrogesterone facility in Udaipur, Rajasthan; launch of ~150 SKUs with DMF-grade APIs and Nobeglar insulin glargine (Anti-Diabetic Launch of the Year); Phase 1 completion of NCE molecule GPR 119 for obesity/metabolic disorders; and incorporation of a wholly-owned subsidiary Mankind Pharma LLC in Russia in August 2025 for business expansion.